As a result of the ongoing shortage of platinum-based chemotherapy, G1 Therapeutics, Inc. lowered its full year 2023 net revenue guidance. The Company expects to generate between $44 million and $47 million in COSELA net revenue in 2023. G1's product revenue guidance is based on expectations for continued acceleration of sales performance of COSELA in the U.S.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.3 USD | -0.30% | -19.32% | +8.20% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.20% | 173M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- GTHX Stock
- News G1 Therapeutics, Inc.
- G1 Therapeutics, Inc. Lowers Net Revenue Guidance for the Full Year 2023